InSilico-Lilly Deal Valued Up to $2.75bn InSilico and Eli Lilly announced a deal on Mar 29, 2026 worth up to $2.75bn; the headline cap exceeds typical AI-pharma collaborations and hinges on clinical translation.

InSilico-Lilly Deal Valued Up to $2.75bn: InSilico and Eli Lilly announced a deal on Mar 29, 2026 worth up to $2.75bn; the headline cap exceeds typical AI-pharma collaborations and hinges on clinical… 👈 Read full analysis #InSilico #EliLilly #PharmaPartnership #AIDrugDiscovery #ClinicalTranslation

Astellas Partners with Sangamo for $20M to Revolutionize Neurological Gene Therapy Astellas is taking a significant step forward in its mission to enhance its neurological gene therapy capabilities by paying Sangamo Therapeutics $20 million upfront in a new agreement. This partnersh...

www.linkedin.com/pulse/astell...

Astellas Partners with Sangamo for $20M to Revolutionize Neurological Gene Therapy

kstrategyand.com/pharma-news

#Astellas #SangamoTherapeutics #GeneTherapy #STACBBB #NeurologicalDiseases #BloodBrainBarrier #PharmaPartnership #Humanteconomy #Humantec #KStrategyand